Hypotestosteronemia is frequent in ST-elevation myocardial infarction patients and is associated with coronary microvascular obstruction

Background Gonadal function is thought to be involved in existing atherosclerotic plaques stabilization and might affect reperfusion after primary percutaneous coronary intervention (pPCI). We aimed to compare the prevalence of hypotestosteromenia between ST-elevation myocardial infarction (STEMI) and stable angina (SA) patients and between patients with and without microvascular obstruction (MVO). Design Cross-sectional observational study. Methods Males with STEMI (n = 70, age 57.1 ± 7.8 years) or with stable angina (n = 30, age 59.9 ± 8.4 years) were enrolled. Angiographic MVO (angio-MVO) was defined as final TIMI flow 2 or final TIMI flow 3 with MBG ≤ 2 while electrocardiographic MVO (ECG-MVO) as a ST-segment resolution <70% at 90 minutes post-pPCI. Variables associated with STEMI and MVO were assessed among clinical, angiographic and laboratory data including testosterone (T) and insulin-like factor 3 (INSL-3), a marker of Leydig cells function. Hypotestosteronemia was defined as T < 2.50 ng/ml with INSL-3 < 305.5 pg/ml. Results Hypotestosteronemia was detected in 32 (45.7%) STEMI patients and in 4 (13.3%) SA patients (p = 0.003). STEMI patients presenting with angio-MVO were more frequently hypotestosteronemic as compared with those without (60.9% vs 38.3%, p = 0.043). Hypotestosteronemia prevalence was higher among STEMI patients presenting with ECG-MVO as compared with those without (69.0% vs 31.7%, p = 0.003). At multivariate analysis hypotestosteronemia independently predicted both angio-MVO (OR = 4.47, 95% CI 1.30–15.36, p = 0.018) and ECG-MVO (OR = 7.56, 95% CI 2.20–25.99, p = 0.001). Conclusions Our study shows higher prevelence of hypotestosteronemia among STEMI patients as compared with SA patients and among STEMI patients with MVO as compared with those without, thus suggesting a possible role of T deficiency in coronary instability and MVO pathogenesis.

[1]  K. Cao,et al.  Testosterone is negatively associated with the severity of coronary atherosclerosis in men. , 2012, Asian journal of andrology.

[2]  V. Massheimer,et al.  Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway. , 2012, The Journal of endocrinology.

[3]  M. Grant,et al.  Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. , 2012, Blood.

[4]  Hong Jiang,et al.  Low testosterone level in middle-aged male patients with coronary artery disease. , 2011, European journal of internal medicine.

[5]  F. Burzotta,et al.  Angiographic patterns of myocardial reperfusion after primary angioplasty and ventricular remodeling , 2011, Coronary artery disease.

[6]  H. Völzke,et al.  Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia , 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[7]  R. Vettor,et al.  Insulin‐like factor 3 as a marker of testicular function in obese men , 2009, Clinical endocrinology.

[8]  P. Algra,et al.  Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. , 2008, Journal of the American College of Cardiology.

[9]  D. Pennell,et al.  Effects of Oral Testosterone Treatment on Myocardial Perfusion and Vascular Function in Men With Low Plasma Testosterone and Coronary Heart Disease , 2008, The American journal of cardiology.

[10]  Xiaoying Li,et al.  Inhibition of oxidative-stress-induced platelet aggregation by androgen at physiological levels via its receptor is associated with the reduction of thromboxane A2 release from platelets , 2007, Steroids.

[11]  E. Romagnoli,et al.  Relation of myocardial blush grade to microvascular perfusion and myocardial infarct size after primary or rescue percutaneous coronary intervention. , 2007, American Journal of Cardiology.

[12]  G. Rosano,et al.  Low testosterone levels are associated with coronary artery disease in male patients with angina , 2007, International Journal of Impotence Research.

[13]  N. Rifai,et al.  Androgens and Diabetes in Men , 2007, Diabetes Care.

[14]  C. Foresta,et al.  Reduced number of circulating endothelial progenitor cells in hypogonadal men. , 2006, The Journal of clinical endocrinology and metabolism.

[15]  H. Okut,et al.  The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting. , 2006, International journal of cardiology.

[16]  J. Kaufman,et al.  The decline of androgen levels in elderly men and its clinical and therapeutic implications. , 2005, Endocrine reviews.

[17]  B. Gersh,et al.  Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. , 2005, European heart journal.

[18]  E. Antman,et al.  Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. , 2004, American heart journal.

[19]  K. Channer,et al.  The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. , 2004, The Journal of clinical endocrinology and metabolism.

[20]  G. Parodi,et al.  Impact of Microvascular Dysfunction on Left Ventricular Remodeling and Long-Term Clinical Outcome After Primary Coronary Angioplasty for Acute Myocardial Infarction , 2004, Circulation.

[21]  R. Schwinger,et al.  Administration of testosterone is associated with a reduced susceptibility to myocardial ischemia. , 2003, Endocrinology.

[22]  V. Miller,et al.  Endothelium-dependent responses in coronary arteries are changed with puberty in male pigs. , 2003, American journal of physiology. Heart and circulatory physiology.

[23]  A. von Eckardstein,et al.  Androgens and coronary artery disease. , 2003, Endocrine reviews.

[24]  K. Channer,et al.  The vasodilatory action of testosterone: a potassium‐channel opening or a calcium antagonistic action? , 2003, British journal of pharmacology.

[25]  M. Boyanov,et al.  Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency , 2003, The aging male : the official journal of the International Society for the Study of the Aging Male.

[26]  A. Hofman,et al.  Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. , 2002, The Journal of clinical endocrinology and metabolism.

[27]  İ. Can,et al.  Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. , 2001, European heart journal.

[28]  M. Romano [Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. A randomized, double-blind, placebo-controlled study]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[29]  J. Féher,et al.  In vitro effects of different steroid hormones on superoxide anion production of human neutrophil granulocytes , 2000, Steroids.

[30]  H. Suryapranata,et al.  Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. , 1998, Circulation.

[31]  B. Gümüş,et al.  Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study. , 1997, Japanese heart journal.

[32]  C. Christiansen,et al.  The relationship of natural androgens to coronary heart disease in males: a review. , 1996, Atherosclerosis.

[33]  M. Mattei,et al.  Structural organization of the porcine and human genes coding for a Leydig cell-specific insulin-like peptide (LEY I-L) and chromosomal localization of the human gene (INSL3). , 1994, Genomics.

[34]  C. Glueck,et al.  Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. , 1993, The Journal of laboratory and clinical medicine.

[35]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[36]  Y. Hishikawa,et al.  Circadian rhythm of serum testosterone and its relation to sleep: comparison with the variation in serum luteinizing hormone, prolactin, and cortisol in normal men. , 1980, The Journal of clinical endocrinology and metabolism.